PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17612778-8	2007	This study shows that conversion from CsA to tacrolimus therapy leads to a reversal of the CsA-induced bone loss, which can probably be mediated by downregulation of IL-1beta, IL-6, and TNF-alpha production.	Tacrolimus	45-55	interleukin 6	Rattus norvegicus	176-180	
17367747-5	2007	More specifically, Tacrolimus suppressed the expression of serum interleukin (IL-1beta), tumour necrosis factor (TNF-alpha), IL-6, airpouch exudate PGE(2) and leukocytosis usually observed after the induction of periodontitis.	Tacrolimus	19-29	interleukin 6	Rattus norvegicus	125-129	
17367747-6	2007	Tacrolimus treatment in periodontitis-induced rats conferred protection against the inflammation-induced tissue and bone loss associated with periodontitis, through a mechanism involving IL-1beta, TNF-alpha and IL-6.	Tacrolimus	0-10	interleukin 6	Rattus norvegicus	211-215	
15551000-9	2004	Therapeutic treatment with FK506 reduced the elevated level of IL-6, but not IL-1beta, in paw tissue.	Tacrolimus	27-32	interleukin 6	Rattus norvegicus	63-67	
17133350-8	2007	In addition to its inhibition of calcineurin activity, FK506 administration totally suppressed the exercise-induced IL-6 gene transcription, likely by an inhibition of p38 activation.	Tacrolimus	55-60	interleukin 6	Rattus norvegicus	116-120	
15390105-8	2005	In FK506-treated rats, a significant reduction of IL-1beta, IL-6, and TNF-alpha expression was observed 12 h after reperfusion.	Tacrolimus	3-8	interleukin 6	Rattus norvegicus	60-64	
15551000-13	2004	FK506 may improve arthritis in established stages of CIA, by reducing the elevated level of IL-6.	Tacrolimus	0-5	interleukin 6	Rattus norvegicus	92-96	
10648038-0	2000	FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis.	Tacrolimus	0-5	interleukin 6	Rattus norvegicus	78-91	
15035807-3	2003	FK506 (tacrolimus), an immunosuppressant, is known to reduce the activation of microglia in vitro and affect the expression of various cytokines like interleukin-1, interleukin-6 and tumor necrosis factor.	Tacrolimus	0-5	interleukin 6	Rattus norvegicus	165-178	
15035807-3	2003	FK506 (tacrolimus), an immunosuppressant, is known to reduce the activation of microglia in vitro and affect the expression of various cytokines like interleukin-1, interleukin-6 and tumor necrosis factor.	Tacrolimus	7-17	interleukin 6	Rattus norvegicus	165-178	
12030571-7	2002	Tacrolimus and dexamethasone decreased IL-6, iNOS and MCP-1.	Tacrolimus	0-10	interleukin 6	Rattus norvegicus	39-43	
14528517-12	2003	CONCLUSION: FK506 is more effective than MTX in reducing elevated levels of inflammatory cytokines TNF-a, IL-1beta, and IL-6 in established stages of AIA.	Tacrolimus	12-17	interleukin 6	Rattus norvegicus	120-124	
11354410-9	2001	Although CSF levels of IL-6 and TNFalpha were completely suppressed by tacrolimus at all time points and at both concentrations, CSF levels of glutamate and hypoxanthine, as well as edema formation, were only marginally influenced.	Tacrolimus	71-81	interleukin 6	Rattus norvegicus	23-27	
10648038-9	2000	The elevated expression of IL-6 and NO characteristic of chronic joint inflammation in the serum and in joint tissue was significantly reduced by FK506 treatment.	Tacrolimus	146-151	interleukin 6	Rattus norvegicus	27-31	
35413717-10	2022	Tacrolimus treatment ameliorated mesangial alterations by suppressing the expressions of Th17-related cytokines such as IL-17 and IL-6.	Tacrolimus	0-10	interleukin 6	Rattus norvegicus	130-134	
7539555-9	1995	Cellular expression of IL-1 alpha, IL-2, IL-6, gamma-INF, FGF, and TGF-beta mRNA was suppressed with FK506 to below isograft levels, and clinical rejection was not observed with the doses, routes, and schedules used.	Tacrolimus	101-106	interleukin 6	Rattus norvegicus	41-45	
7686193-0	1993	FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion.	Tacrolimus	0-6	interleukin 6	Rattus norvegicus	84-97	
7686193-8	1993	Based upon these data, it is probable that FK 506 attenuates hepatic ischemia/reperfusion injury, at least in part, by reducing TNF and IL-6 levels.	Tacrolimus	43-49	interleukin 6	Rattus norvegicus	136-140	
32749698-8	2021	The results demonstrated that Tac prolonged the allografts survival and attenuated inflammation injury, and decreased the percentage frequencies of T follicular helper (Tfh) cells in peripheral blood mononuclear cells and inhibited B-cell lymphoma 6 (Bcl-6) and IL-6 expression in Tfh cells.	Tacrolimus	30-33	interleukin 6	Rattus norvegicus	262-266	
23334350-14	2013	CONCLUSIONS: Tacrolimus could be effective in uveitis treatment by neutralizing or decreasing the levels of cytokines such as TNF-alpha, IL-1 and IL-6 that have a critical part in the pathogenesis of uveitis.	Tacrolimus	13-23	interleukin 6	Rattus norvegicus	146-150	
30254425-8	2018	Additionally, the expression of IL-1beta, IL-6, monocyte chemotactic protein-1, macrophage inflammatory protein-1alpha and TGF-beta were significantly decreased by tacrolimus.	Tacrolimus	164-174	interleukin 6	Rattus norvegicus	42-46	
27572744-9	2017	Moreover, the results in hypoxia-treated primary spinal cord microglia confirmed the effect of FK-506 on TNF-a, IL-1b, and IL-6 expression and NF-kappaB activation.	Tacrolimus	95-101	interleukin 6	Rattus norvegicus	123-127	
25752645-9	2015	Importantly, we showed that calcineurin-dependent NFAT3 nuclear translocation was essential to AngII-mediated IL-6 transcription, QL mimicked the effect of FK506, the calcineurin inhibitor, on suppression of IL-6 expression and stress fibres formation.	Tacrolimus	156-161	interleukin 6	Rattus norvegicus	110-114	
25752645-9	2015	Importantly, we showed that calcineurin-dependent NFAT3 nuclear translocation was essential to AngII-mediated IL-6 transcription, QL mimicked the effect of FK506, the calcineurin inhibitor, on suppression of IL-6 expression and stress fibres formation.	Tacrolimus	156-161	interleukin 6	Rattus norvegicus	208-212	
24468714-8	2014	The expression of IL-6 and Ki67 was significantly increased in the insulin and tacrolimus groups compared to the portal stenosis group.	Tacrolimus	79-89	interleukin 6	Rattus norvegicus	18-22	
21820512-9	2011	Reduced mRNA expression levels of CD4, IFN-gamma, IL-6, IL-10, iNOS, NFkappaB, TNF-alpha and MCP-1 (p <= 0.05) were observed in tacrolimus treated animals compared to sirolimus.	Tacrolimus	131-141	interleukin 6	Rattus norvegicus	50-54